Cargando…

Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study

Radioisotope-guided sentinel lymph node dissection (sLND) has shown high diagnostic reliability in prostate (PCa) and other cancers. To overcome the limitations of the radioactive tracers, magnetometer-guided sLND using superparamagnetic iron oxide nanoparticles (SPIONs) has been successfully used i...

Descripción completa

Detalles Bibliográficos
Autores principales: Winter, Alexander, Engels, Svenja, Goos, Philipp, Süykers, Marie-Christin, Gudenkauf, Stefan, Henke, Rolf-Peter, Wawroschek, Friedhelm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017225/
https://www.ncbi.nlm.nih.gov/pubmed/31877623
http://dx.doi.org/10.3390/cancers12010032
_version_ 1783497153544454144
author Winter, Alexander
Engels, Svenja
Goos, Philipp
Süykers, Marie-Christin
Gudenkauf, Stefan
Henke, Rolf-Peter
Wawroschek, Friedhelm
author_facet Winter, Alexander
Engels, Svenja
Goos, Philipp
Süykers, Marie-Christin
Gudenkauf, Stefan
Henke, Rolf-Peter
Wawroschek, Friedhelm
author_sort Winter, Alexander
collection PubMed
description Radioisotope-guided sentinel lymph node dissection (sLND) has shown high diagnostic reliability in prostate (PCa) and other cancers. To overcome the limitations of the radioactive tracers, magnetometer-guided sLND using superparamagnetic iron oxide nanoparticles (SPIONs) has been successfully used in PCa. This prospective study (SentiMag Pro II, DRKS00007671) determined the diagnostic accuracy of magnetometer-guided sLND in intermediate- and high-risk PCa. Fifty intermediate- or high-risk PCa patients (prostate-specific antigen (PSA) ≥ 10 ng/mL and/or Gleason score ≥ 7; median PSA 10.8 ng/mL, IQR 7.4–19.2 ng/mL) were enrolled. After the intraprostatic SPIONs injection a day earlier, patients underwent magnetometer-guided sLND and extended lymph node dissection (eLND, followed by radical prostatectomy. SLNs were detected in in vivo and in ex vivo samples. Diagnostic accuracy of sLND was assessed using eLND as the reference. SLNs were detected in all patients (detection rate 100%), with 447 sentinel lymph nodes SLNs (median 9, IQR 6–12) being identified and 966 LNs (median 18, IQR 15–23) being removed. Thirty-six percent (18/50) of patients had LN metastases (median 2, IQR 1–3). Magnetometer-guided sLND had 100% sensitivity, 97.0% specificity, 94.4% positive predictive value, 100% negative predictive value, 0.0% false negative rate, and 3.0% additional diagnostic value (LN metastases only in SLNs outside the eLND template). In vivo, one positive SLN/LN-positive patient was missed, resulting in a sensitivity of 94.4%. In conclusion, this new magnetic sentinel procedure has high accuracy for nodal staging in intermediate- and high-risk PCa. The reliability of intraoperative SLN detection using this magnetometer system requires verification in further multicentric studies.
format Online
Article
Text
id pubmed-7017225
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70172252020-02-28 Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study Winter, Alexander Engels, Svenja Goos, Philipp Süykers, Marie-Christin Gudenkauf, Stefan Henke, Rolf-Peter Wawroschek, Friedhelm Cancers (Basel) Article Radioisotope-guided sentinel lymph node dissection (sLND) has shown high diagnostic reliability in prostate (PCa) and other cancers. To overcome the limitations of the radioactive tracers, magnetometer-guided sLND using superparamagnetic iron oxide nanoparticles (SPIONs) has been successfully used in PCa. This prospective study (SentiMag Pro II, DRKS00007671) determined the diagnostic accuracy of magnetometer-guided sLND in intermediate- and high-risk PCa. Fifty intermediate- or high-risk PCa patients (prostate-specific antigen (PSA) ≥ 10 ng/mL and/or Gleason score ≥ 7; median PSA 10.8 ng/mL, IQR 7.4–19.2 ng/mL) were enrolled. After the intraprostatic SPIONs injection a day earlier, patients underwent magnetometer-guided sLND and extended lymph node dissection (eLND, followed by radical prostatectomy. SLNs were detected in in vivo and in ex vivo samples. Diagnostic accuracy of sLND was assessed using eLND as the reference. SLNs were detected in all patients (detection rate 100%), with 447 sentinel lymph nodes SLNs (median 9, IQR 6–12) being identified and 966 LNs (median 18, IQR 15–23) being removed. Thirty-six percent (18/50) of patients had LN metastases (median 2, IQR 1–3). Magnetometer-guided sLND had 100% sensitivity, 97.0% specificity, 94.4% positive predictive value, 100% negative predictive value, 0.0% false negative rate, and 3.0% additional diagnostic value (LN metastases only in SLNs outside the eLND template). In vivo, one positive SLN/LN-positive patient was missed, resulting in a sensitivity of 94.4%. In conclusion, this new magnetic sentinel procedure has high accuracy for nodal staging in intermediate- and high-risk PCa. The reliability of intraoperative SLN detection using this magnetometer system requires verification in further multicentric studies. MDPI 2019-12-20 /pmc/articles/PMC7017225/ /pubmed/31877623 http://dx.doi.org/10.3390/cancers12010032 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Winter, Alexander
Engels, Svenja
Goos, Philipp
Süykers, Marie-Christin
Gudenkauf, Stefan
Henke, Rolf-Peter
Wawroschek, Friedhelm
Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
title Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
title_full Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
title_fullStr Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
title_full_unstemmed Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
title_short Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
title_sort accuracy of magnetometer-guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in prostate cancer: the sentimag pro ii study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017225/
https://www.ncbi.nlm.nih.gov/pubmed/31877623
http://dx.doi.org/10.3390/cancers12010032
work_keys_str_mv AT winteralexander accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy
AT engelssvenja accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy
AT goosphilipp accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy
AT suykersmariechristin accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy
AT gudenkaufstefan accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy
AT henkerolfpeter accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy
AT wawroschekfriedhelm accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy